Nursing Considerations for Adverse Events From CAR T-Cell Therapy, ONS Voice

Nursing Considerations for Adverse Events From CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy offers options for pediatric patients with relapsed or refractory acute lymphoblastic leukemia, but it comes with a unique set of side effects that can range from mild to severe. As the primary patient providers, oncology nurses are often the very first to identify signs and symptoms of adverse events and acute switches in patients’ status. Contine reading

Novartis’ CAR-T gene therapy, the very first approved by FDA, to cost $475, 000

Novartis’ CAR-T gene therapy, the very first approved by FDA, to cost $475,000

Published: Aug 31, two thousand seventeen Two:14 p.m. ET

Concerns about how the therapy would be priced preceded its Wednesday approval

EmmaCourt

Novartis AG’s CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the very first gene therapy to be available in the U.S. Contine reading